Arthritis Clinical Trials in Chicago
View 59 new treatments for Arthritis in Chicago, IL, and nearby areas, such as Naperville. Every day, Power helps hundreds of arthritis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
NSAIDs for Knee Osteoarthritis
Research Clinic, Chicago + 1 more
This trial is testing naproxen, a common pain reliever, in people with painful knee osteoarthritis. Naproxen helps reduce swelling and pain by blocking certain chemicals in the body. Participants will receive naproxen to compare its effects. Naproxen has been shown to be an effective and well-tolerated drug for the treatment of osteoarthritis of the hip and knee in previous studies.Show More
Recruiting
Phase 4
Est. 6 - 12 Weeks
Thomas J Schnitzer, MD, PhD
Principal Investigator
Baricitinib vs TNF Inhibitors for Rheumatoid Arthritis
Eli Lilly Clinic, Chicago + 2 more
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Guselkumab for Psoriatic Arthritis
Janssen Clinic, Hinsdale + 2 more
This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 3 - 6 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
COVID-19 Vaccines for Rheumatic Diseases
Research Clinic, Chicago + 1 more
Based on the experience with influenza, pneumococcal, and shingles vaccinations in rheumatic disease populations, it is clear that some disease modifying anti-rheumatic drugs and the immunomodulatory therapies used to treat immune-mediated inflammatory diseases have the capacity to blunt immune responses to COVID-19 vaccines. Several studies have suggested that patients with autoimmune conditions may be at increased risk of poor COVID-19 outcomes. There is an urgent need to better clarify the immunogenicity and safety of COVID-19 vaccines in people living with rheumatic disease who use immunomodulatory therapies. Boosters at annual or other frequency are available, and there is a need to understand whether these vaccines can be given concurrently with other routine vaccines.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Pain Medication for Knee Osteoarthritis
Research Clinic, Chicago + 1 more
This is a clinical trial of people who have pain due to knee osteoarthritis at Northwestern University Feinberg School of Medicine. The study will last for about 20 weeks. 180 qualified participants will be randomly assigned in a 1:1:1 ratio (60 participants per group) to one of three treatment groups: duloxetine, celecoxib, or placebo. Participants will have an Xray, knee MRI, brain MRI, blood draws, pain sensitivity testing, and asked to fill out questionnaires. The purpose of this study is to try to predict which participants will respond to the treatment.Show More
Recruiting
Phase 4
Est. 6 - 12 Weeks
Thomas J Schnitzer, MD, PhD
Principal Investigator
Baricitinib for Rheumatoid Arthritis
Eli Lilly Clinic, Chicago + 4 more
This trial compares the safety of two treatments for rheumatoid arthritis, focusing on the risk of blood clots. One treatment is baricitinib, an oral medication used for moderate to severe cases.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 5 - 8 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
TG-C for Knee Osteoarthritis
Kolon TissueGene Clinic, Chicago + 4 more
This trial tests TG-C, an injection into the knee, for people with moderate to severe knee osteoarthritis. It aims to see if TG-C can reduce pain and improve knee function by potentially altering the disease. The study will monitor patients for safety and effectiveness over time. TG-C has been previously studied for its potential to improve knee joint function and reduce pain in osteoarthritis patients.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
David W Romness, MD
Principal Investigator
Tildrakizumab for Psoriatic Arthritis
Sun Clinic, Morton Grove + 4 more
This trial is testing tildrakizumab, a medication that reduces inflammation, in patients with active Psoriatic Arthritis who haven't tried certain other treatments. It works by blocking a protein to help manage symptoms. Tildrakizumab is approved for treating moderate to severe plaque psoriasis.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Non-Surgical Interventions for Knee Osteoarthritis
Research Clinic, Chicago + 1 more
There is an urgent public health need to reduce reliance on opioids for effective long-term pain management, particularly in knee osteoarthritis (KOA). This effectiveness trial will compare commonly recommended treatments to reduce pain and functional limitations in KOA.These results will lead to improved patient selection for treatment and inform evidence based guidelines by offering well-tested, effective, non-surgical alternatives.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Steven Cohen, MD
Principal Investigator
Upadacitinib for Axial Spondyloarthritis
AbbVie Clinic, Chicago + 3 more
This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently. The main objectives of this protocol are: * To evaluate the efficacy of upadacitinib compared with placebo on reduction of signs and symptoms in adults with active axial spondyloarthritis (axSpA) including biologic disease-modifying antirheumatic drug inadequate responders (bDMARD-IR) ankylosing spondylitis (AS) (Study 1) and non-radiographic axial spondyloarthritis (nr-axSpA) (Study 2). * To assess the safety and tolerability of upadacitinib in adults with active axSpA including bDMARD-IR AS (Study 1) and nr-axSpA (Study 2). * To evaluate the safety and tolerability of upadacitinib in extended treatment in adult participants with active axSpA including bDMARD-IR AS who have completed the Double-Blind Period (Study 1) and nr-axSpA who have completed the Double-Blind Period (Study 2). * To evaluate the maintenance of disease control after withdrawal of upadacitinib.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
ABBVIE INC.
Study Director
Page 1 of 9
Frequently Asked Questions
Explore related conditions